Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8906MR)

This product GTTS-WQ8906MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8906MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8080MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ10701MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ6030MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6529MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ2304MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ1052MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ13714MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ66MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW